-
BRIT J RADIOL 2021 10.1259/bjr.20210352
Long-term follow-up of oxaliplatin-induced liver damage in patients with colorectal cancer
Cha1, DI; Song, KD; Ha, SY; Hong, JY; Hwang, JA; Ko, SE
View PubMed
-
EUR J CANCER 2021 10.1016/j.ejca.2021.03.024
Association between non-alcoholic fatty liver disease and the risk of biliary tract cancers: A South Korean nationwide cohort study
Park1, JH; Hong, JY; Kwon, M; Lee, J; Han, K; Han, IW; Kang, W; Park, JK
View PubMed
-
EUR RADIOL 2021 10.1007/s00330-021-08094-3
Prediction of epithelial-to-mesenchymal transition molecular subtype using CT in gastric cancer
Cha1, DI; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Kim, SW; Choi, D
View PubMed
-
CANCER MANAG RES 2021 10.2147/CMAR.S309092
Real-World, Single-Center Data for Lenalidomide Plus Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Transformed Follicular Lymphoma
Lee1, YP; Hong, JY; Yoon, SE; Cho, J; Shim, JH; Bang, Y; Kim, WS; Kim, SJ
View PubMed
-
ESMO OPEN 2021 10.1016/j.esmoop.2021.100049
Liposomal irinotecan plus fluorouracil/leucovorin versus FOLFIRINOX as the second-line chemotherapy for patients with metastatic pancreatic cancer: a multicenter retrospective study of the Korean Cancer Study Group (KCSG)
Park1, HS; Kang, B; Chon, HJ; Im, HS; Lee, CK; Kim, I; Kang, MJ; Hwang, JE; Bae, WK; Cheon, J; Park, JO; Hong, JY; Kang, JH; Kim, JH; Lim, SH; Kim, JW; Kim, JW; Yoo, C; Choi, HJ
View PubMed
-
ONCOLOGY-BASEL 2021 10.1159/000514404
Programmed Death Ligand 1 Expression as a Prognostic Marker in Patients with Advanced Biliary Tract Cancer
Kim1, H; Kim, J; Byeon, S; Jang, KT; Hong, JY; Lee, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
ANN ONCOL 2021 10.1016/j.annonc.2020.11.017
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial
Park1, SH; Lim, DH; Sohn, TS; Lee, J; Zang, DY; Kim, ST; Kang, JH; Oh, SY; Hwang, IG; Ji, JH; Shin, DB; Yu, JI; Kim, KM; An, JY; Choi, MG; Lee, JH; Kim, S; Hong, JY; Park, JO; Park, YS; Lim, HY; Bae, JM; Kang, WK
View PubMed
-
THER ADV MED ONCOL 2021 10.1177/1758835921992992
Clinical sequencing to assess tumor mutational burden as a useful biomarker to immunotherapy in various solid tumors
Kim1, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, KM; Kim, ST
View PubMed
-
CANCERS 2021 10.3390/cancers13010059
Impact of Radiotherapy on Kidney Function among Patients Who Received Adjuvant Treatment for Gastric Cancer: Logistic and Linear Regression Analyses
Park1, JS; Il Yu, J; Lim, D; Nam, H; Kim, YI; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM
View PubMed
-
GENOME MED 2021 10.1186/s13073-021-00826-w
Comprehensive molecular characterization of gastric cancer patients from phase II second-line ramucirumab plus paclitaxel therapy trial
Kim1, ST; Sa, JK; Oh, SY; Kim, K; Hong, JY; Kang, WK; Kim, KM; Lee, J
View PubMed
-
IN VIVO 2021 10.21873/invivo.12284
ATM Expression as a Prognostic Marker in Patients With Advanced Biliary Tract Cancer Treated With First-line Gemcitabine and Platinum Chemotherapy
Kim1, H; Kim, ST; Yoo, KH; Hong, JY; Park, YS; Lim, HY; Park, JO
View PubMed
-
J CANCER 2021 10.7150/jca.49176
Prognostic Factors of Survival with Aflibercept and FOLFIRI (fluorouracil, leucovorin, irinotecan) as Second-line Therapy for Patients with Metastatic Colorectal Cancer
Kim1, J; Kim, H; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
THER ADV MED ONCOL 2020 10.1177/1758835920965842
Clinical and molecular distinctions in patients with refractory colon cancer who benefit from regorafenib treatment
Lee1, MS; Cho, HJ; Hong, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Cho, YB; Kim, ST
View PubMed
-
CANCER IMMUNOL IMMUN 2020 10.1007/s00262-020-02794-3
Incorporating sarcopenia and inflammation with radiation therapy in patients with hepatocellular carcinoma treated with nivolumab
Kim1, N; Yu, JI; Park, HC; Yoo, GS; Choi, C; Hong, JY; Lim, HY; Lee, J; Choi, MS; Lee, JE; Kim, K
View PubMed
-
RADIOTHER ONCOL 2020 10.1016/j.radonc.2020.07.043
Effect of baseline sarcopenia on adjuvant treatment for D2 dissected gastric cancer Analysis of the ARTIST phase III trial
Yu1, JI; Choi, C; Lee, J; Kang, WK; Park, SH; Kim, ST; Hong, JY; Kim, S; Sohn, TS; Lee, JH; An, JY; Choi, MG; Bae, JM; Kim, KM; Han, H; Kim, K; Nam, H; Lim, DH
View PubMed
-
CANCER EPIDEM BIOMAR 2020 10.1158/1055-9965.EPI-20-0594
Obesity Has a Stronger Relationship with Colorectal Cancer in Postmenopausal Women than Premenopausal Women
Chang1, JW; Shin, DW; Do Han, K; Jeon, KH; Yoo, JE; Cho, IY; Choi, YJ; Hong, JY
View PubMed
-
GASTRIC CANCER 2020 10.1007/s10120-020-01124-x
Prognostic significance of sarcopenia in microsatellite-stable gastric cancer patients treated with programmed death-1 inhibitors
Kim1, YY; Lee, J; Jeong, WK; Kim, ST; Kim, JH; Hong, JY; Kang, WK; Kim, KM; Sohn, I; Choi, D
View PubMed
-
ANN SURG ONCOL 2020 10.1245/s10434-020-08408-7
Regional Lymph Node Metastasis of Scalp Angiosarcoma A Detailed Clinical Observation Study of 40 Cases
Kang1, Y; Bae, J; Choi, S; Jang, KT; Yu, J; Hong, JY; Lim, SY; Jeong, HS
View PubMed
-
TARGET ONCOL 2020 10.1007/s11523-020-00731-z
Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma A Multicenter Retrospective Cohort Study
Oh1, CR; Hong, JY; Kim, JH; Lee, JS; Kim, HS; Kim, TW; Ahn, JH; Kim, JE
View PubMed
-
THER ADV MED ONCOL 2020 10.1177/1758835920926796
First-in-human phase I trial of anti-hepatocyte growth factor antibody (YYB101) in refractory solid tumor patients
Kim1, ST; Hong, JY; Park, SH; Park, JO; Park, YW; Park, N; Lee, H; Hong, SH; Lee, SJ; Song, SW; Kim, K; Park, YS; Lim, HY; Kang, WK; Nam, H; Lee, JW; Park, K; Kim, KM; Lee, J
View PubMed
-
LIVER INT 2020 10.1111/liv.14496
Regorafenib in previously treated advanced hepatocellular carcinoma: Impact of prior immunotherapy and adverse events
Yoo1, C; Byeon, S; Bang, Y; Cheon, J; Kim, JW; Kim, JH; Chon, HJ; Kang, B; Kang, MJ; Kim, I; Hwang, JE; Kang, JH; Lee, MA; Hong, JY; Lim, HY; Ryoo, BY
View PubMed
-
Transl Cancer Res 2020 10.21037/tcr-19-1876
Claudin 18.2 expression in various tumor types and its role as a potential target in advanced gastric cancer
Hong1, JY; An, JY; Lee, J; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, KM; Kang, WK; Kim, ST
View PubMed
-
TARGET ONCOL 2020 10.1007/s11523-020-00713-1
Impact of Prior Ramucirumab Use on Treatment Outcomes of Checkpoint Inhibitors in Advanced Gastric Cancer Patients
Kim1, J; Byeon, S; Kim, H; Yeo, JH; Hong, JY; Lee, J; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
TARGET ONCOL 2020 10.1007/s11523-020-00706-0
Use of Gefitinib in EGFR-Amplified Refractory Solid Tumors: An Open-Label, Single-Arm, Single-Center Prospective Pilot Study
Byeon1, S; Hong, JY; Lee, J; Nam, DH; Park, SH; Park, JO; Park, YS; Lim, HY; Kang, WK; Kim, ST
View PubMed
-
PATHOL RES PRACT 2020 10.1016/j.prp.2020.152820
TPK1 as a predictive marker for the anti-tumour effects of simvastatin in gastric cancer
Hong1, JY; Kim, HJ; Kim, K; Hong, J; Kim, JE; Byeon, SJ; Lee, IK; Kim, KM; Shim, M; Park, SH; Park, JO; Park, YS; Lim, HY; Kim, ST; Lee, J; Kang, WK
View PubMed
-
ESMO OPEN 2020 10.1136/esmoopen-2020-000670
Clinical scoring system for the prediction of survival of patients with advanced gastric cancer
Kim1, J; Hong, JY; Kim, ST; Park, SH; Jekal, SY; Choi, JS; Chang, DK; Kang, WK; Seo, SW; Lee, J
View PubMed
-
Genome Med 2020 10.1186/s13073-020-0717-8
Comprehensive pharmacogenomic characterization of gastric cancer
Sa1, JK; Hong, JY; Lee, IK; Kim, JS; Sim, MH; Kim, HJ; An, JY; Sohn, TS; Lee, JH; Bae, JM; Kim, S; Kim, KM; Kim, ST; Park, SH; Park, JO; Lim, HY; Kang, WK; Her, NG; Lee, Y; Cho, HJ; Shin, YJ; Kim, M; Koo, H; Kim, M; Seo, YJ; Kim, JY; Choi, MG; Nam, DH; Lee, J
View PubMed
-
TARGET ONCOL 2020 10.1007/s11523-019-00691-z
Pemetrexed/Erlotinib as a Salvage Treatment in Patients with High EGFR-Expressing Metastatic Colorectal Cancer Following Failure of Standard Chemotherapy: A Phase II Single-Arm Prospective Study
Kim1, ST; Hong, JY; Lee, JY; Park, JO; Lim, HY; Kang, WK; Park, YS
View PubMed
-
LEUKEMIA LYMPHOMA 2020 10.1080/10428194.2019.1709831
Distinct clinical characteristics at diagnosis in patients with late relapses compared with early relapses of diffuse large B-cell lymphoma treated with R-CHOP
Kang1, J; Chae, H; Hong, JY; Yoon, DH; Kim, S; Park, JS; Lee, SW; Park, CS; Ryu, JS; Huh, J; Suh, C
View PubMed
-
J ONCOL 2020 10.1155/2020/4659062
Detection of Fusion Genes Using a Targeted RNA Sequencing Panel in Gastrointestinal and Rare Cancers
Lee1, SJ; Hong, JY; Kim, K; Kim, KM; Kang, SY; Lee, T; Kim, ST; Park, SH; Park, YS; Lim, HY; Kang, WK; Lee, J; Park, JO
View PubMed
-
CANCER DISCOV 2019 10.1158/2159-8290.CD-19-0442
Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial
Lee1, J; Kim, ST; Kim, K; Lee, H; Kozarewa, I; Mortimer, PGS; Odegaard, JI; Harrington, EA; Lee, J; Lee, T; Oh, SY; Kang, JH; Kim, JH; Kim, Y; Ji, JH; Kim, YS; Lee, KE; Kim, J; Sohn, TS; An, JY; Choi, MG; Lee, JH; Bae, JM; Kim, S; Kim, JJ; Min, YW; Min, BH; Kim, NKD; Luke, S; Kim, YH; Hong, JY; Park, SH; Park, JO; Park, YS; Lim, HY; Talasaz, A; Hollingsworth, SJ; Kim, KM; Kang, WK
View PubMed
-
PLoS One 2019 10.1371/journal.pone.0215080
Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system
Cho1, JH; Kim, JS; Kim, ST; Hong, JY; Park, JO; Park, YS; Nam, DH; Lee, DW; Lee, J
View PubMed
